K
KeyMed Biosciences Inc
HKEX:2162
KeyMed Biosciences Inc
HKEX:2162
Price:
36.4 HKD
0.69%
Market Closed
Updated:
May 22, 2024
Section:
Relative Value
The Relative Value of one KeyMed Biosciences Inc stock under the Base Case scenario is 48.65 HKD. Compared to the current market price of 36.4 HKD, KeyMed Biosciences Inc is Undervalued by 25%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
48.65
HKD
Undervaluation 25%
K
Valuation Multiples
Multiples Across Competitors
Competitors Multiples
KeyMed Biosciences Inc Competitors
KeyMed Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
K
|
KeyMed Biosciences Inc
HKEX:2162
|
10.2B HKD | 26.7 | -26.3 | -19.4 | -16.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.7B USD | 5.3 | 48.4 | 13.5 | 20.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.9B USD | 5.7 | 44.9 | 18.9 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.2B USD | 11.2 | 28.4 | 23.8 | 24.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 8.4 | 28.4 | 23 | 25.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.3B AUD | 6.3 | 36.3 | 21.9 | 27.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.8B USD | 3.1 | 173.2 | 8.8 | 11.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
55B USD | 10.7 | -9.2 | -10.3 | -9.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.2B USD | 3.4 | 28.4 | 14.5 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.6T KRW | 17.7 | 72 | 44.1 | 60.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
